DK0941318T5 - Håndvægtformede konstruerede ekspressionssystemer til genterapi - Google Patents

Håndvægtformede konstruerede ekspressionssystemer til genterapi

Info

Publication number
DK0941318T5
DK0941318T5 DK97949949T DK97949949T DK0941318T5 DK 0941318 T5 DK0941318 T5 DK 0941318T5 DK 97949949 T DK97949949 T DK 97949949T DK 97949949 T DK97949949 T DK 97949949T DK 0941318 T5 DK0941318 T5 DK 0941318T5
Authority
DK
Denmark
Prior art keywords
expression
dumbbell
construct
shaped gene
gene expression
Prior art date
Application number
DK97949949T
Other languages
English (en)
Other versions
DK0941318T3 (da
Inventor
Burghardt Wittig
Claas Junghans
Original Assignee
Soft Gene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soft Gene Gmbh filed Critical Soft Gene Gmbh
Publication of DK0941318T3 publication Critical patent/DK0941318T3/da
Application granted granted Critical
Publication of DK0941318T5 publication Critical patent/DK0941318T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97949949T 1996-11-13 1997-11-13 Håndvægtformede konstruerede ekspressionssystemer til genterapi DK0941318T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19648625A DE19648625A1 (de) 1996-11-13 1996-11-13 Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
PCT/DE1997/002704 WO1998021322A1 (de) 1996-11-13 1997-11-13 Design-prinzip für die konstruktion von expressionskonstrukten für die gentherapie

Publications (2)

Publication Number Publication Date
DK0941318T3 DK0941318T3 (da) 2001-05-21
DK0941318T5 true DK0941318T5 (da) 2002-02-18

Family

ID=7812619

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97949949T DK0941318T5 (da) 1996-11-13 1997-11-13 Håndvægtformede konstruerede ekspressionssystemer til genterapi

Country Status (8)

Country Link
US (2) US6451593B1 (da)
EP (1) EP0941318B9 (da)
AT (1) ATE198767T1 (da)
AU (1) AU5308698A (da)
DE (3) DE19648625A1 (da)
DK (1) DK0941318T5 (da)
ES (1) ES2155702T4 (da)
WO (1) WO1998021322A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE19753182A1 (de) * 1997-11-21 1999-07-29 Claas Junghans Topologisch fixierte matrixgebundene Nukleinsäure
DE19826758C1 (de) * 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
CA2365981A1 (en) * 1999-03-24 2000-09-28 Board Of Regents, The University Of Texas System Linear and circular expression elements
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
DE10025920A1 (de) * 2000-05-27 2001-12-06 Mologen Forschungs Entwicklung Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge
DE10119005A1 (de) * 2001-04-18 2002-10-24 Roche Diagnostics Gmbh Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen
AU2002329176A1 (en) * 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
PT1432805E (pt) * 2001-10-02 2005-10-31 Mologen Ag Estrutura de expressao do dna para tratamento de infeccoes de leishmaniose
ES2254758T3 (es) * 2001-10-02 2006-06-16 Mologen Ag Medicamento para mejorar la respuesta inmunitaria.
US20150050317A1 (en) * 2013-08-19 2015-02-19 Mologen Ag Means for Eliciting an Immune Response and a Method Therefor
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
ATE352632T1 (de) * 2002-07-19 2007-02-15 Mologen Ag Dna-expressionskonstrukt zur multiplen genexpression
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ES2270120T3 (es) 2002-09-23 2007-04-01 Mologen Ag Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina.
AU2003222173A1 (en) * 2003-04-01 2004-11-23 Patrick J. Branigan Nucleic acid compositions and methods for use
WO2004111247A1 (de) * 2003-06-10 2004-12-23 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
EP1615663B1 (de) 2003-10-24 2007-12-26 Mologen AG Mittel zur behandlung von infektionen mit leishmanien
CN102994515A (zh) 2003-12-30 2013-03-27 莫洛根股份公司 同种异基因肿瘤治疗剂
US7613295B2 (en) * 2004-02-18 2009-11-03 Harris Corporation Cryptographic device and associated methods
DK1716234T3 (da) 2004-02-20 2014-01-20 Mologen Ag Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr
EP1749096B1 (de) * 2004-05-28 2013-07-17 Mologen AG Herstellungsverfahren geeigneter dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
US8420611B2 (en) * 2004-08-12 2013-04-16 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
WO2007031333A2 (en) 2005-09-15 2007-03-22 Novosom Ag Improvements in or relating to amphoteric liposomes
DE112006003704A5 (de) * 2005-11-25 2008-10-23 Mologen Ag DNA-Konstrukte zur spezifischen Hemmung der Genexpression durch RNA-Interferenz
EP2094238A2 (en) 2006-10-13 2009-09-02 Novosom AG Improvements in or relating to amphoteric liposomes
WO2008095027A2 (en) * 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
DE102007029471A1 (de) 2007-06-20 2008-12-24 Novosom Ag Neue fakultativ kationische Sterole
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
KR101954912B1 (ko) 2009-07-09 2019-03-08 노보솜 베르발퉁스 게엠베하 이미노 지질을 포함하는 양쪽성 리포좀
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
GB2483462A (en) 2010-09-08 2012-03-14 Mologen Ag Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
IN2014DN00221A (da) 2011-07-25 2015-06-05 Oxford Nanopore Tech Ltd
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
BR112015021788B1 (pt) 2013-03-08 2023-02-28 Oxford Nanopore Technologies Plc Métodos para mover uma ou mais helicases imobilizadas, para controlar o movimento de um polinucleotídeo alvo, para caracterizar um polinucleotídeo alvo e para controlar o carregamento de uma ou mais helicases em um polinucleotídeo alvo, uso de um poro de transmembrana e de um potencial aplicado e de um ou mais espaçadores, complexo, e, kit
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
GB201418159D0 (en) * 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CA2965661C (en) 2014-10-23 2023-09-26 Ricardo Mancebo Reagents and methods for isothermal chain reaction
SI3240801T1 (sl) 2014-12-31 2021-04-30 Checkmate Pharmaceuticals, Inc. Kombinirana imunoterapija tumorja
GB201509578D0 (en) 2015-06-03 2015-07-15 Univ Singapore Vectors
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
SG11202009647VA (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
EP3854419A1 (en) * 2020-01-24 2021-07-28 Univerzita Karlova, Lekarska fakulta v Plzni Dna conjugate and method of transformation of genes into cells
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
EP4337177A1 (en) 2021-05-11 2024-03-20 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1293559B1 (en) 1994-01-21 2005-07-27 Powderject Vaccines, Inc. Gas driven gene delivery instrument
DE4416784A1 (de) * 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
FR2731014B1 (fr) 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19510696A1 (de) 1995-03-14 1996-09-19 Soft Gene Gmbh Vorrichtung zur Druckverteilung im Kopfstück einer Apparatur zum ballistischen Transfer von Zellen
FR2732971B1 (fr) * 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

Also Published As

Publication number Publication date
DE59702936D1 (de) 2001-02-22
DK0941318T3 (da) 2001-05-21
ES2155702T4 (es) 2002-12-16
ATE198767T1 (de) 2001-02-15
EP0941318B1 (de) 2001-01-17
US6451593B1 (en) 2002-09-17
US20030054392A1 (en) 2003-03-20
WO1998021322A1 (de) 1998-05-22
ES2155702T3 (es) 2001-05-16
HK1024714A1 (en) 2000-10-20
AU5308698A (en) 1998-06-03
US7074772B2 (en) 2006-07-11
EP0941318A1 (de) 1999-09-15
DE19648625A1 (de) 1998-05-14
DE19781276D2 (de) 1999-09-30
EP0941318B9 (de) 2001-12-19

Similar Documents

Publication Publication Date Title
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
AU7599500A (en) Novel gl50 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
DE60144021D1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
AU2002211446A1 (en) 32144, a human fatty acid amide hydrolase and uses thereof
EP1412374A4 (en) NEW PGC-1 ISOFORMS AND THEIR USES
WO2000052164A3 (en) Potassium channel molecules and uses therefor
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
AU2001253258A1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
WO2001032872A3 (en) Twik potassium channel molecules and uses therefor
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
MXPA03002557A (es) Interactores de canales del potasio y sus usos.
WO2002024898A3 (en) 47647, a human lipase and uses therefor
WO2002020739A3 (en) Human matrix metalloproteinase
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2001081584A3 (en) 27960, a novel ubiquitin conjugating enzyme family member and uses therefor